

World Journal of *Gastrointestinal Oncology*

World J Gastrointest Oncol 2022 June 15; 14(6): 1067-1217



REVIEW

- 1067** Circular RNAs in hepatocellular carcinoma: Recent advances
Niu ZS, Wang WH
- 1086** Practical considerations for colorectal cancer screening in older adults
Gornick D, Kadakuntla A, Trovato A, Stetzer R, Tadros M
- 1103** Fibrolamellar hepatocellular carcinoma: A rare but unpleasant event
Abdelhamed W, El-Kassas M

MINIREVIEWS

- 1115** Can dietary flavonoids be useful in the personalized treatment of colorectal cancer?
Pereira-Wilson C

ORIGINAL ARTICLE

Basic Study

- 1124** Glutamine deprivation impairs function of infiltrating CD8⁺T cells in hepatocellular carcinoma by inducing mitochondrial damage and apoptosis
Wang W, Guo MN, Li N, Pang DQ, Wu JH

Retrospective Cohort Study

- 1141** Does the addition of Braun anastomosis to Billroth II reconstruction on laparoscopic-assisted distal gastrectomy benefit patients?
Li XG, Song QY, Wu D, Li S, Zhang BL, Zhang LY, Guan D, Wang XX, Liu L
- 1148** Contemporary, national patterns of surgery after preoperative therapy for stage II/III rectal adenocarcinoma
Soriano C, Bahnson HT, Kaplan JA, Lin B, Moonka R, Pham HT, Kennecke HF, Simianu V

Retrospective Study

- 1162** Clinicopathological differences, risk factors and prognostic scores for western patients with intestinal and diffuse-type gastric cancer
Díaz del Arco C, Estrada Muñoz L, Ortega Medina L, Molina Roldán E, Cerón Nieto MÁ, García Gómez de las Heras S, Fernández Aceñero MJ

Observational Study

- 1175** Characterizing the patient experience during neoadjuvant therapy for pancreatic ductal adenocarcinoma: A qualitative study
Stevens L, Brown ZJ, Zeh R, Monsour C, Wells-Di Gregorio S, Santry H, Ejaz AM, Pawlik TM, Cloyd JM

Randomized Controlled Trial

- 1187** Biofeedback therapy combined with Baduanjin on quality of life and gastrointestinal hormone level in patients with colorectal cancer
Zhou XD, Wei HG, Ai FL

META-ANALYSIS

- 1199** Does chronic kidney disease affect the complications and prognosis of patients after primary colorectal cancer surgery?
Liu XY, Zhang B, Cheng YX, Tao W, Yuan C, Wei ZQ, Peng D

LETTER TO THE EDITOR

- 1210** Hepatocellular carcinoma and immunotherapy: Beyond immune checkpoint inhibitors
Abushukair HM, Saeed A
- 1213** Insight on BRAF^{V600E} mutated colorectal cancer immune microenvironment
Abushukair HM, Zaitoun SM, Saeed A

CORRECTION

- 1216** Correction to "MicroRNA-320a suppresses tumor progression by targeting PBX3 in gastric cancer and is downregulated by DNA methylation"
Li YS, Zou Y, Dai DQ

ABOUT COVER

Editorial Board Member of *World Journal of Gastrointestinal Oncology*, Tamás Micsik, MD, PhD, Assistant Professor, The First Department of Pathology and Experimental Cancer Research, Semmelweis University Budapest, Budapest h-1085, Hungary. micsikt@gmail.com

AIMS AND SCOPE

The primary aim of *World Journal of Gastrointestinal Oncology* (WJGO, *World J Gastrointest Oncol*) is to provide scholars and readers from various fields of gastrointestinal oncology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJGO mainly publishes articles reporting research results and findings obtained in the field of gastrointestinal oncology and covering a wide range of topics including liver cell adenoma, gastric neoplasms, appendiceal neoplasms, biliary tract neoplasms, hepatocellular carcinoma, pancreatic carcinoma, cecal neoplasms, colonic neoplasms, colorectal neoplasms, duodenal neoplasms, esophageal neoplasms, gallbladder neoplasms, *etc.*

INDEXING/ABSTRACTING

The WJGO is now indexed in Science Citation Index Expanded (also known as SciSearch®), PubMed, PubMed Central, and Scopus. The 2021 edition of Journal Citation Reports® cites the 2020 impact factor (IF) for WJGO as 3.393; IF without journal self cites: 3.333; 5-year IF: 3.519; Journal Citation Indicator: 0.5; Ranking: 163 among 242 journals in oncology; Quartile category: Q3; Ranking: 60 among 92 journals in gastroenterology and hepatology; and Quartile category: Q3. The WJGO's CiteScore for 2020 is 3.3 and Scopus CiteScore rank 2020: Gastroenterology is 70/136.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: *Ying-Yi Yuan*; **Production Department Director:** *Xiang Li*; **Editorial Office Director:** *Ya-Juan Ma*.

NAME OF JOURNAL

World Journal of Gastrointestinal Oncology

ISSN

ISSN 1948-5204 (online)

LAUNCH DATE

February 15, 2009

FREQUENCY

Monthly

EDITORS-IN-CHIEF

Monjur Ahmed, Florin Burada

EDITORIAL BOARD MEMBERS

<https://www.wjgnet.com/1948-5204/editorialboard.htm>

PUBLICATION DATE

June 15, 2022

COPYRIGHT

© 2022 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>



Correction to "MicroRNA-320a suppresses tumor progression by targeting PBX3 in gastric cancer and is downregulated by DNA methylation"

Yong-Shuang Li, Ying Zou, Dong-Qiu Dai

Specialty type: Oncology

Provenance and peer review:

Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0
Grade B (Very good): B, B
Grade C (Good): C
Grade D (Fair): 0
Grade E (Poor): 0

P-Reviewer: Hori T, Japan;

Kapritsou M, Greece; Moshref L, Saudi Arabia

Received: October 25, 2021

Peer-review started: October 25, 2021

First decision: April 17, 2022

Revised: April 19, 2022

Accepted: April 22, 2022

Article in press: April 22, 2022

Published online: June 15, 2022



Yong-Shuang Li, Ying Zou, Dong-Qiu Dai, Department of Gastrointestinal Surgery, The Fourth Affiliated Hospital of China Medical University, Shenyang 110032, Liaoning Province, China

Corresponding author: Dong-Qiu Dai, MD, PhD, Chief Doctor, Professor, Surgical Oncologist, Department of Gastrointestinal Surgery, The Fourth Affiliated Hospital of China Medical University, No. 4 Chongshan East Road, Shenyang 110032, Liaoning Province, China. daidq63@163.com

Abstract

We rechecked the original data of Figure 3, Part.B, and found that 0 h group in the BGC-823 cell wound scratch assay was misapplied. Therefore, we are writing to apply for the modification of Figure 3, Part.B.

Key Words: Correction; Gastric cancer; miRNA-320a; DNA methylation

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: This is a correction to "MicroRNA-320a suppresses tumor progression by targeting PBX3 in gastric cancer and is downregulated by DNA methylation".


Citation: Li YS, Zou Y, Dai DQ. Correction to "MicroRNA-320a suppresses tumor progression by targeting PBX3 in gastric cancer and is downregulated by DNA methylation". *World J Gastrointest Oncol* 2022; 14(6): 1216-1217

URL: <https://www.wjgnet.com/1948-5204/full/v14/i6/1216.htm>

DOI: <https://dx.doi.org/10.4251/wjgo.v14.i6.1216>

CORRECTION

Correction to: Li YS, Zou Y, Dai DQ. MicroRNA-320a suppresses tumor progression by targeting PBX3 in gastric cancer and is downregulated by DNA methylation. *World J Gastrointest Oncol* 2019; 11(10): 842-856 PMID: 31662823 DOI: 10.4251/wjgo.v11.i10.842.



DOI: 10.4251/wjgo.v14.i6.1216 Copyright ©The Author(s) 2022.

Figure 1 Part.B. Overexpression of miR-320a suppressed gastric cancer cell migration and invasion.

We recently read our manuscript published in the *World Journal of Gastrointestinal Oncology* (Manuscript NO: 48527, DOI: 10.4251/wjgo.v11.i10.842), we have carefully rechecked the original data of Figure 3, Part.B, and found that 0 h group in the BGC-823 cell wound scratch assay was misapplied. Therefore, we are writing to apply for the modification of Figure 3, Part.B. The revised images are shown in this Correction (Figure 1). We feel deeply sorry for this mistake during the proofreading process. This correction does not alter any interpretation of the results or conclusion of this study[1].

We apologize for any inconvenience caused by this mistake.

FOOTNOTES

Author contributions: Li YS and Dai DQ submitted the final manuscript and all authors read and approved the final version.

Conflict-of-interest statement: All authors declare that they have no conflicts of interest.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: China

ORCID number: Yong-Shuang Li 0000-0002-0474-853X; Ying Zou 0000-0003-2067-0995; Dong-Qiu Dai 0000-0002-1154-3276.

S-Editor: Wang LL

L-Editor: A

P-Editor: Wang LL

REFERENCES

- 1 Li YS, Zou Y, Dai DQ. MicroRNA-320a suppresses tumor progression by targeting PBX3 in gastric cancer and is downregulated by DNA methylation. *World J Gastrointest Oncol* 2019; **11**: 842-856 [PMID: 31662823 DOI: 10.4251/wjgo.v11.i10.842]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: bpgoffice@wjgnet.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

